# A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1

> **NCT07275606** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **ViiV Healthcare** · enrollment: 66 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Oral CAB
- **DRUG:** IM CAB LA

## Key facts

- **NCT ID:** NCT07275606
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2029-10-10
- **Final completion:** 2029-10-10
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07275606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07275606, "A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07275606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*